• EBCC 10, European Breast Cancer Conference, 9-11 March 2016

    EBCC 10 European Breast Cancer Conference 9-11 March 2016 - IGEA Medical

    This is a manifesto calling for all patients with breast cancer in Europe to be cared for only in specialist breast units. It will be presented at a special session at EBCC-10 on 9 March 2016.

    IGEA will attend with booth, number 10100. Come to visit us!

  • New NICE guidelines for Melanoma: NICE recommend Electrochemotherapy as option for palliative treatment for in transit metastases

    Electrochemotherapy has been included by NICE in the new guidelines "Melanoma: assessment and management" has as palliative treatment for in-transit metastases.

    The details are as follows...

  • Abstract acceptance for American Society of Clinical Oncology (A.S.C.O.) Chicago may 28-june 2, 2015

    The abstract from the IMI-GIDO (Italian melanoma intergroup - italian group dermato oncology) Italian group has been accepted for A.S.C.O.

    With over 30,000 attendees from across the globe this one of the key annual Oncology meetingsand therefore a number of your KOL’s and customers will be attending.

  • 11th European Association Dermato Oncology (EADO) & 8th world meeting of interdisciplinary melanoma/skin cancer centers - Marseille Oct 28-31, 2015

    IGEA will attend with booth, (11 EADO October 28-31 2015 Marseille), which is the  largest dermato oncology/melanoma conference outside US.

    The congress is biennal and it is jointly organized with Europa Donna (EU breast cancer coalition, EORTC breast cancer group, EUSOMA, EU society of breast cancer specialists). 

  • ABC3 Lisbon Nov 5-7, 2015

    IGEA will attend with booth the Advanced Breast Cancer conference ABC3 Lisbon Nov 5-7, 2015. 

    This is the 3rd international consensus conference on Advanced Breast Cancer. Its primary aim is to define guidelines for the treatment of advanced breast cancer.

  • 3rd Congress od European ORL - HNS Prague June 7-11, 2015

    IGEA will attend with booth. The 3rd Congress of European ORL-HNS is the most significant European event organized in the field of ORL-HNS.

    It is our pleasure to inform that the abstract Electrochemotherapy for the treatment of head and neck cancer: rationale, indications, methods and results presentation of a multi-Institutional European Working Group (EURECA) protocol from the ORL Dept of University Hospital Pavia - Italy has been accepted for ORAL presentation at the Congress. Date and time of the presentation: Tuesday 9 June from 15:00–16:30

  • Electrochemotherapy: NICE guidance for metastasis in the skin

     NICE guidance for metastasis in the skin

    Electrochemotherapy receives NICE (National Institute for Health and Clinical Excellence – UK) positive guidance for metastasis in the skin (for tumours of non skin origin and melanoma), and for primary basal cell carcinoma and primary squamous cell carcinoma. 

    This is a very important achievement that confirms effectiveness and safety of Electrochemotherapy.


  • IGEA Worldwide


    Since 1980, the year it was founded, IGEA has been working to provide patients with effective therapies.

    Research and intellectual curiosity have always distinguished the work of IGEA, and over the years have enabled IGEA to become the leading company in the field of Clinical Biophysics. Individuals and their ideas, knowledge built on a solid scientific foundation and product quality are the foundation on which IGEA decided to build its future.

  • Oncology

    IGEA works on the treatment of cutaneous and subcutaneous tumours of electrochemotherapy, an efficacious technique that can guarantee that drugs and genetic material can penetrate the poorly permeable tumour cell.

    Its use is particularly indicated in patients with local recurrences or cutaneous metastases of breast cancer, head of neck cancers and stage III B/C and IV M1 melanoma. 

  • Orthopaedics


    IGEA's aim is to make the best technology to cure the patient, available to the clinician, through the many applications of Clinical Biophysics, designed to promote the reparative processes in bone tissue and cartilage.

    Major clinical studies have demonstrated the efficacy of IGEA medical devices in noticeably reducing fracture healing times, without resorting to surgical procedures. 

Clinical biophysics

The best technology against tumours
The best technology against tumours

To discover the importance of electrochemotherapy for the treatment of cutaneous and subcutaneous tumours, and to find out more about the functions of the Cliniporator, for an efficacious and safe treatment with minimal side effects, visit the dedicated oncology section. 

Physics and biology for bone health
Physics and biology for bone health

To find out more about the central role of biological factors in promoting osteogenetic and chondroprotective activity, and to read about the whole range of IGEA’s innovative medical devices, visit the dedicated orthopaedics section.